Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133071 | 0.85 | TSHR (0.46) | TSHRLMNAHCAR2 | |
| SCHEMBL576784 | 0.84 | — | — | |
| Bicarbonate SCHEMBL28358527 | 0.84 | TSHR (0.33) | TSHRLMNAHCAR2 | |
| SCHEMBL11144445 | 0.83 | MAPK1 (0.37) | — | |
| SCHEMBL14715673 | 0.81 | TSHR (0.42) | TSHRLMNAHCAR2 | |
| SCHEMBL319242 | 0.81 | — | — | |
| SCHEMBL28358262 | 0.81 | MAPT (0.34) | — | |
| SCHEMBL28358446 | 0.81 | MAPT (0.34) | — | |
| SCHEMBL22558112 | 0.81 | — | — | |
| SCHEMBL28358260 | 0.81 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119147674-A | Method for detecting halogenated ester in cefamate drug | 浙江普洛得邦制药有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3856747-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3749652-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | The Johns Hopkins University (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020064661-A1 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-02 | — | — | WO | disclosed |
| CN-110655490-A | Halogenated imidazole compounds, preparation method and application | 重庆迈迪生医药科技有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019157338-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2015108835-A1 | 3,3-DISUBSTITUTED-1-HYDROXYTRIAZ-1-ENE 2-OXIDES AND WOUND-HEALING COMPOSITIONS USING THEM | SARMONT LLC (US) | 2015-07-23 | — | — | WO | disclosed |
| CN-103420980-A | Dabigatran derivatives | BEIJING MEIBEITA DRUG RES CO LTD | 2013-12-04 | — | — | CN | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-0474243-B1 | 1-Methylcarbapenem derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5208348-A | Intermediates for thienamycin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1993-05-04 | — | — | US | disclosed |
| US-5153187-A | Microbiocides having stability against dehydropeptidase and high absorrbability by oral administration | TANABE SEIYAKU CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0474243-A1 | 1-Methylcarbapenem derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0060904-B1 | A PROCESS FOR MAKING VICINAL EPOXIDES AND ALKYL HALIDES OR ALKYLENE DIHALIDES FROM CARBONATE ESTERS | THE DOW CHEMICAL COMPANY (US) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TSHR 3968/4885LMNA 4568/4885HCAR2 70/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | TSHR 4060/4885LMNA 4576/4885HCAR2 68/4885 |
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | TSHR 4759/4885LMNA 542/4885HCAR2 4202/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TSHR 4759/4885LMNA 542/4885HCAR2 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.